.png)
Cleveland Clinic Study for Early Detection of Ovarian Cancer
Ovarian Cancer Risk
Women with BRCA1 or BRCA2 gene mutations have a high risk of ovarian cancer (40-60%) compared to the general population (1-2%).
Early Detection Challenges
Current methods like transvaginal ultrasound and CA-125 blood tests have low effectiveness in early detection of ovarian cancer.
Study Goals
-
Investigate whether changes in cell signaling (integrin/syndecan) found in breast tissues of BRCA mutation carriers are also present in ovarian tissues.
-
Explore if these changes can be used as new biomarkers for early detection of ovarian cancer.
Amy Exhibited Early Signs of Ovarian Cancer but Was Unable to Recognize Them
In its initial stages, ovarian cancer symptoms often resemble common female issues, making it challenging for even doctors to suspect cancer. If Amy had known she carried the BRCA1 gene mutation, it might have led to an earlier diagnosis, but she was the first in her family to face this illness and therefore was unaware of her genetic risk.
By the time ovarian cancer is identified at Stage 3 or Stage 4, the disease is typically incurable, and, as Amy's experience shows, managing it becomes a prolonged and painful struggle. Early detection remains the most effective approach. This is why Amy's Foundation seeks funding to develop reliable early detection methods.
Please consider donating to help Amy fulfill her mission of aiding other women in finding early detection and preventing them from undergoing the same suffering she endured. Your contribution can make a significant difference in advancing this critical cause.
Research Approach
Specific Aim 1
Examine integrin/syndecan signaling in ovarian tissues from BRCA mutation carriers and compare with normal and cancerous ovarian tissues using advanced technology (Digital Spatial Profiling).
Specific Aim 2
Measure levels of integrin/syndecan biomarkers in blood samples to assess their potential for early cancer detection.
